Search Results
Mar 24, 2026, 10:47 ET Fosun Pharma Announces 2025 Annual Results
(luvometinib Tablet) received approval for two indications, filling the gap in the treatment of rare tumors in China; the innovative small-molecule CDK4/6 inhibitor Futuoning® (fovinaciclib citrate capsules) was launched for two indications in China, bringing a brand-new treatment option for
More news about: Fosun Pharma
Mar 24, 2026, 03:43 ET DualityBio (9606.HK) Announces 2025 Annual Results
advanced/unresectable or metastatic HR-positive/HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy, CDK4/6 inhibitor, with or without chemotherapy for unresectable or metastatic disease, or developed disease recurrence during or within 6 months of completing
More news about: Duality Biotherapeutics, Inc.
Mar 24, 2026, 02:20 ET 映恩生物（9606.HK）公佈2025年度業績
突變，且在接受第三代 EGFR 酪氨酸激酶抑制劑（TKI）及鉑類化療期間或之後出現疾病進展；2025 年 12 月，DB-1310 再獲 FDA 快速通道認定，適用於治療晚期 / 不可切除或轉移性 HR 陽性 / HER2 陰性（IHC 0、IHC 1 + 或 IHC 2+/ISH-）乳腺癌的成年患者，此類患者曾接受過內分泌治療、CDK4/6 抑制劑（無論是否聯合化療）用於治療不可切除或轉移性疾病，或在輔助化療期間或完成後 6 個月內出現疾病復發。深化全球合作，釋放戰略協同效應映恩生物持續推進映恩飛輪模式，深化全球合作，旨在實現自主研發資產價值的最大化。公司已構建起穩健的全球合作版圖，簽署的6項對外授權及共同開發協議總價值超過
More news about: Duality Biotherapeutics, Inc.
Mar 20, 2026, 09:03 ET Henlius Reports 2025 Results: Sustained Growth in Both Revenue and Profit, Advancing Innovation Validation and Global Operations
564.2%, further strengthening its position as a leading brand in extended adjuvant therapy for HER2-positive early-stage breast cancer. The innovative CDK4/6 inhibitor FUTUONING (fovinaciclib) achieved its first prescriptions in the second half of 2025 and was included in the updated National Reimbursement
More news about: Henlius
Mar 18, 2026, 07:58 ET Biotheryx Announces First Patient Dosed in the Dose Expansion Phase of BTX-9341-101 for the Treatment of HR+/HER2- Breast Cancer
of CDK4/6, important targets for a range of cancers and clinically validated in HR+/HER2- breast cancer. In preclinical breast cancer models, BTX-9341 demonstrated superiority to CDK4/6 inhibitors through potent and highly selective catalytic degradation of CDK4 and CDK6, robust inhibition of CDK2 and
More news about: Biotheryx, Inc.
Feb 11, 2026, 08:30 ET Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook
activity as a monotherapy as well as (Z)-endoxifen as a combination therapy with two partner drugs: 1) abemaciclib (VERZENIO®), a cyclin-dependent kinase (CDK) 4/6 inhibitor marketed by Eli Lilly and Company; and 2) elagolix (ORILISSA®), a prescription medicine used to treat moderate to severe pain associated
More news about: Atossa Therapeutics Inc
Feb 06, 2026, 04:00 ET Kelun-Biotech Announces Fourth Indication for Sacituzumab Tirumotecan (sac-TMT) Approved by NMPA in HR+/HER2- Breast Cancer
metastases, 75.9% had liver metastases; 52.9% were HER2-zero (IHC 0), while 47.1% were HER2-low (IHC 1+ or IHC 2+/ISH-). All patients had received prior CDK4/6 inhibitor and taxane therapy; 56.6% had received ≥2 lines of prior chemotherapy in the advanced or metastatic setting.Results showed that sac-TMT
More news about: Kelun-biotech
Feb 05, 2026, 09:35 ET $207B Market Shift: The Race for Fast Track Approval in Oncology
designation for zovegalisib in combination with fulvestrant for PIK3CA-mutant HR+/HER2- locally advanced or metastatic breast cancer following progression on CDK4/6 inhibitor treatment. The designation was supported by clinical data from the ReDiscover trial with 600mg BID fasted and 400mg BID fed doses showing
More news about: USA News Group
Jan 30, 2026, 09:41 ET Nexpart Multi-Seller is Driving Growth for Dealerships and Fixed Ops at NADA
platform is helping grow OEM parts sales organically with reduced friction. Nexpart supports direct integrations into over 30 DMS systems including CDK, Reynolds & Reynolds, Dealertrack DMS and many more.
More news about: WHI SOLUTIONS
Jan 29, 2026, 05:01 ET Group 1 Automotive Reports Fourth Quarter and Full Year 2025 Financial Results
hurricanes and snow storms, and employment compensation costs associated with the cybersecurity incident experienced by third-party software provider, CDK Global LLC in June 2024. Because these non-core charges and gains materially affect the Company's financial condition or results in the specific period
More news about: Group 1 Automotive, Inc.
Jan 28, 2026, 09:15 ET Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment
also reported initial ACR-2316 Phase 1 data showing tumor shrinkage in endometrial cancer, SCLC and squamous NSCLC, with ACR-6840 nominated as its next CDK11 inhibitor development candidate.ImmunityBio (NASDAQ: IBRX)
More news about: USA News Group
Jan 20, 2026, 11:15 ET El lanzamiento de los kits SwiftFluo® TR-FRET de Sino Biological marca una nueva era
fluorescencia.Optimizados para el perfilado de más de 60 tirosina quinasas (TK), 150 serina/treonina quinasas (STK) y 15 quinasas dependientes de ciclina (CDK), estos kits SwiftFluo® TR-FRET ofrecen una amplia cobertura en las vías de señalización clave. Además de los kits, Sino Biological ofrece sustratos
More news about: Sino Biological, Inc.
Jan 20, 2026, 10:00 ET La commercialisation par Sino Biological des kits SwiftFluo® TR-FRET ouvre une nouvelle ère pour le criblage à haut débit des inhibiteurs de kinases.
fluorescence.Optimisés pour le profilage de plus de 60 tyrosine kinases (TK), 150 sérine/thréonine kinases (STK) et 15 kinases cycline-dépendantes (CDK), les kits SwiftFluo® TR-FRET procurent une large couverture des principales voies de signalisation. En dehors des kits, Sino Biological propose
More news about: Sino Biological, Inc.
Jan 14, 2026, 12:12 ET Clovity Adds Former CoreTrust CEO Mahesh Shah as Operating Advisor to Accelerate AI-Powered Atlassian Growth in Regulated Sectors
where he helped stand up and scale the business in its target market.He has also held senior executive roles at:CDK Global – EVP & Chief Product and Technology OfficerDXC Technology – SVP & General ManagerHewlett-Packard (HP)
More news about: Clovity
Dec 22, 2025, 03:00 ET Menarini Silicon Biosystems annuncia la pubblicazione dei risultati dello studio PACE, che mostrano il valore clinico della conta delle cellule tumorali circolanti con CELLSEARCH® in uno specifico sottotipo di carcinoma mammario metastatico
ormonali (HR+) e HER2-negativo (HER2-), la cui malattia è progredita dopo trattamento con inibitori dell'aromatasi in combinazione con inibitori di CDK4/6 (CDK4/6i). La conta delle CTC si è dimostrata un biomarcatore predittivo indipendente, non influenzato dai fattori di rischio clinici né dai risultati dell'analisi
More news about: Menarini Silicon Biosystems
Dec 22, 2025, 03:00 ET Menarini Silicon Biosystems announces PACE trial biomarker analysis results confirming clinical utility of CELLSEARCH® CTC enumeration to guide treatment decisions in a specific metastatic breast cancer subtype
randomized to receive either endocrine monotherapy or combination therapy consisting of a doublet (endocrine therapy plus a CDK4/6 inhibitor) or a triplet regimen (endocrine therapy plus a CDK4/6 inhibitor and an immune checkpoint inhibitor). Based on their CTC level, patients were classified into two prognostic
More news about: Menarini Silicon Biosystems
Dec 22, 2025, 03:00 ET Menarini Silicon Biosystems gibt die Veröffentlichung der Ergebnisse der Biomarker-Analyse der PACE-Studie bekannt, die den klinischen Nutzen der CELLSEARCH® CTC-Zählung für die Behandlung eines bestimmten Subtyps von metastasiertem Brustkrebs bestätigt
endokrine Monotherapie oder eine Kombinationstherapie bestehend aus einer Doppeltherapie (endokrine Therapie plus CDK4/6-Inhibitor) oder einer Dreifachtherapie (endokrine Therapie plus CDK4/6-Inhibitor und Immun-Checkpoint-Inhibitor). Basierend auf ihrem CTC-Spiegel wurden die Patienten in zwei Prognosegruppen
More news about: Menarini Silicon Biosystems
Dec 22, 2025, 03:00 ET Menarini Silicon Biosystems announces PACE trial biomarker analysis results confirming clinical utility of CELLSEARCH® CTC enumeration to guide treatment decisions in a specific metastatic breast cancer subtype
randomized to receive either endocrine monotherapy or combination therapy consisting of a doublet (endocrine therapy plus a CDK4/6 inhibitor) or a triplet regimen (endocrine therapy plus a CDK4/6 inhibitor and an immune checkpoint inhibitor). Based on their CTC level, patients were classified into two prognostic
More news about: Menarini Silicon Biosystems
Dec 22, 2025, 03:00 ET Menarini Silicon Biosystems anuncia la publicación de los resultados del ensayo PACE, que confirma la utilidad clínica del recuento de CTC con CELLSEARCH® en un subtipo específico de cáncer de mama metastásico
recibir monoterapia endocrina o terapia combinada consistente en un régimen doble (terapia endocrina más un inhibidor de CDK4/6) o un régimen triple (terapia endocrina más un inhibidor de CDK4/6 y un inhibidor de puntos de control inmunitario). En función de su nivel de CTC, los pacientes se clasificaron en
More news about: Menarini Silicon Biosystems
Dec 22, 2025, 03:00 ET Menarini Silicon Biosystems annonce la publication des résultats de l'essai PACE confirmant l'utilité clinique de l'énumération des CTC avec CELLSEARCH® dans pour un sous-type spécifique de cancer du sein métastatique
endocrinienne, soit une thérapie combinée consistant en un traitement double (thérapie endocrinienne plus inhibiteur de CDK4/6) ou traitement triple (thérapie endocrinienne plus inhibiteur de CDK4/6 et inhibiteur de point de contrôle immunitaire). En fonction de leur taux de CTC, les patientes ont été classées
More news about: Menarini Silicon Biosystems
Dec 17, 2025, 11:00 ET Breast Cancer Drugs Market to Reach USD 57.1 Billion by 2031 as Precision Oncology and Targeted Therapies Redefine Treatment Outcomes
of estrogen and progesterone receptor-positive tumors and the long duration of treatment using hormonal and targeted agents. Continuous innovation in CDK4/6 inhibitors and endocrine combinations continues to expand this segment.HER2-positive breast cancer accounts for approximately 21%
More news about: DataM Intelligence 4 Market Research LLP
Dec 12, 2025, 11:45 ET Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
Randomization was stratified by prior CDK4/6 inhibitor use, the presence of visceral metastases and geographic region. Patients enrolled as first line (1L) treatment for ABC (32%), following disease recurrence on or within 12 months of completing adjuvant AI, with or without CDK4/6 inhibitor for early breast
More news about: Eli Lilly and Company
Dec 10, 2025, 14:16 ET Menarini Group apresenta os dados da fase 2 da combinação de elacestranto (ORSERDU®) em pacientes com câncer de mama metastático (mBC) ER+, HER2- no San Antonio Breast Cancer Symposium 2025 (SABCS)
ESR1 em pacientes com mBC ER+/HER2-, que apresentam progressão da doença em terapia endócrina (ET), com ou sem exposição prévia a inibidores de CDK4/6. Estes resultados atualizados também demonstram que a segurança das combinações são compatíveis com os perfis de segurança conhecidos de cada terapia
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 10, 2025, 14:02 ET Menarini Group presenta datos de combinación de fase 2 de Elacestrant (ORSERDU®) en pacientes con cáncer de mama metastásico (CMM) ER+, con HER2 en el Simposio de Cáncer de Mama 2025 en San Antonio
ER+/HER2-, que experimentan progresión de la enfermedad en terapia endocrina (ET, por sus siglas en inglés), con o sin exposición previa a inhibidores de CDK4/6. Estos resultados actualizados también evidencian que la seguridad de las combinaciones es coherente con los perfiles de seguridad conocidos de cada
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 10, 2025, 10:11 ET Menarini Group、2025年サンアントニオ乳がんシンポジウムにてエラセストラント（ORSERDU®）併用療法の第2相データをER+、HER2-転移性乳がん（mBC）患者を対象に発表
ry B. Convention Center発表者：Aditya Bardiaプレゼンテーションのタイトル：ADELA試験：エラセストラント（ELA）＋エベロリムス（EVE）とELA＋プラセボ（PBO）を比較する、ER+/HER2-の進行乳がん（aBC）患者を対象とした二重盲検・プラセボ対照・無作為化第3相試験（内分泌療法（ET）＋CDK4/6阻害剤（CDK4/6i）治療中に病勢進行を示したESR1変異腫瘍例）アブストラクト番号：1141プレゼンテーション日時：2025年12月10日（水）午後12時30分～午後2時場所：Henry
More news about: Menarini Industrie Farmaceutiche Riunite